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Introduction: We report a phase I trial of photodynamic
therapy (PDT) of carcinoma in situ (CIS) and microinvasive
cancer (MIC) of the central airways with the photosensitizer
(PS) 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a
(HPPH). HPPH has the advantage of minimal general
phototoxicity over the commonly used photosensitizer
porﬁmer sodium (Photofrin; Pinnacle Biologics, Chicago, IL).
Methods: The objectives of this study were (1) to deter-
mine the maximally tolerated light dose at a ﬁxed photo-
sensitizer dose and (2) to gain initial insight into the
effectiveness of this treatment approach. Seventeen patients
with 21 CIS/MIC lesions were treated with HPPH with light
dose escalation starting from 75 J/cm2 and increasing to 85,
95,125, and 150 J/cm,2 respectively. Follow-up bronchos-
copy for response assessment was performed at 1 and 6
months, respectively.
Results: The rate of pathological complete response (CR)
was 82.4% (14 of 17 evaluable lesions; 14 patients) at 1
month and 72.7% (8/11 evaluable lesions; 8 patients) at 6
months. Only four patients developed mild skin erythema.
One of the three patients in the 150 J/cm2 light dose group
experienced a serious adverse event. This patient had res-
piratory distress caused by mucus plugging, which precipi-
tated cardiac ischemia. Two additional patients treated
subsequently at this light dose had no adverse events. The
sixth patient in this dose group was not recruited and the
study was terminated because of delays in HPPH supply.Journal of Thoracic Oncology Vol. 11 No. 2: 234-241However, given the observed serious adverse event, it is
recommended that the light dose does not exceed 125 J/cm2.
Conclusions: PDT with HPPH can be safely used for the
treatment of CIS/MIC of the airways, with potential effec-
tiveness comparable to that reported for porﬁmer sodium
in earlier studies.
 2015 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. All rights reserved.
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Introduction
Non–small cell lung cancer (NSCLC) is the leading cause
of cancer-related mortality, with a low ﬁve-year survival
rate of approximately 15%. Such poor outcomes are
attributed to the largely advanced stages at detection.
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cancer in its early, treatable stages is ongoing.1 The detec-
tion of early-stage central carcinoma in situ (CIS) and
microinvasive carcinoma (MIC) is important, because these
are treatable and patients generally have an excellent
prognosis. CIS/MIC is identiﬁed by bronchoscopic exami-
nation of the proximal central airways, which is frequently
enhanced by techniques like autoﬂuorescence bronchos-
copy (AFB) and narrowband imaging. Surgical resection,
external beam radiation, and bronchoscopic ablative tech-
niques can be used to treat CIS/MIC. Superﬁcial airway
cancers treated by formal surgical resectionmay result in a
signiﬁcant loss of lung function from their usual central
location and frequent multicentricity. A substantial pro-
portion of these patients also have signiﬁcant cardiovas-
cular and pulmonary comorbidities, which preclude
surgical resection. Therefore advanced bronchoscopic
techniques, such as photodynamic therapy (PDT), electro-
cautery, argon plasma coagulation (APC), cryotherapy, and
laser are usually chosen to treat patients with CIS/MIC.2
PDT is light activation of a tumor-localized photosen-
sitizer (PS) to generate cytotoxic reactive oxygen species,
predominantly singlet oxygen, to kill tumors.3 The PS
porﬁmer sodium (Photofrin; Pinnacle Biologics, Chicago,
IL), has regulatory approval in the United States for the
treatment of early- and late-stage endobronchial cancer,
among other indications.4–6 Porﬁmer sodium is the most
commonly used PS for the treatment of early-stage bron-
chogenic carcinoma and is one of the most extensively
studied agents in this setting.7–9 While PDT using porﬁmer
sodium for early-stage lung cancer is generally considered
safe, it is associated with skin phototoxicity, with a re-
ported incidence of sunburn ranging from 13% to 41%
when treating CIS/MIC.8 Patients’ failure to avoid sun-
light and other sources of bright light for 6 weeks post-
treatment contributes to this problem. A number of
second-generation PSs are effective for early endobron-
chial disease PDT9–11 but are not available in United
States. One such chlorin-based second-generation PS, 2-[1-
hexyloxyethyl]-2-devinyl pyropheophorbide-a (HPPH),
developed at Roswell Park Cancer Institute (RPCI), has
much lower risks of phototoxicity and requires post-
treatment sunlight precautions of 7 to 10 days.12 HPPH
also has deeper tissue penetration because it absorbs light
strongly at 665 nm (compared to 630 nm for porﬁmer
sodium). We sought to (1) study the maximally tolerated
light dose (MTD) at a ﬁxed PS dose and (2) gain initial
insight into the effectiveness of this treatment approach.
Methods
Study Design
This was a single-institution, phase 1, dose-ﬁnding,
open label, noncomparative study of HPPH PDT inpatients with bronchogenic CIS or bronchogenic MIC.
The trial (NCI-2010-02114) was conducted at the RPCI
between August 2004 and April 2013. HPPH was used
at a ﬁxed, previously determined systemic dose of
4 mg/m2.7,13–15 The study followed a conventional 3 þ 3
dose escalation scheme that was designed to determine
the MTD.16 Three patients were evaluated at each light
dose cohort. If none of the patients developed dose-
limited toxicity (DLT), the light dose was escalated to
the next higher level. DLTs were deﬁned as grade 3 or
higher systemic toxicity or grade 3 or higher normal
tissue toxicity that was probably or deﬁnitely related to
PDT. If one of the three patients experienced a DLT,
three more patients were recruited at that dose level.
Dose escalation proceeded only if none of the three
additional patients had any DLT. The protocol indicated
that if two or more patients in any group had DLT, dose
escalation would stop. MTD was deﬁned to be the
highest PDT light dose that resulted in two or fewer
instances of DLTs among six patients.
The primary objective of this study was to establish
the safety proﬁle of this treatment approach. The sec-
ondary objective was to gain some preliminary insight
into the treatment response, as determined pathologically
by biopsy specimens obtained at 1 month posttreatment,
where possible at 6 months posttreatment, and by clinical
follow-up for adverse events and for continued surveil-
lance per the guidelines of our screening program. Writ-
ten informed consent was obtained from all patients, and
all protocol-related procedures were approved by the
RPCI Institutional Review Board and overseen by the
RPCI Data Safety and Monitoring Board.Patient Selection
At RPCI, a screening program for high-risk patients
was initiated in 1998 and has been ongoing.17–19 It in-
volves bimodality screening with low-dose non-contrast
enhanced spiral computed tomography (CT) scans of the
chest and AFB in select high-risk patients. This high-risk
patient population includes patients with previously
treated head and neck, lung, and aerodigestive tract can-
cers with no evidence of disease for >1 year. It also
included patients with a smoking history of>20 packs per
year plus additional risk factors like asbestosis, chronic
obstructive pulmonary disease (COPD) with a forced
expiratory volume in 1 second <70% of predicted, or a
ﬁrst-degree relative with lung cancer. Some additional
patients had autoﬂuorescence examination of airway
while undergoing bronchoscopy for clinically suspicious
separate lung lesions. From this cohort, patients with
detectable CIS/MIC were recruited for the current study.
Patients diagnosed with CIS/MIC at outside institutions
were also referred to us for treatment.
Table 1. Patient/Lesion Characteristics
Characteristic
Patients (N ¼ 17)/
Lesions (N ¼ 21)
Median age, y (range) 65 (47–81)
Male:female 12:5
Race
White 16
Asian 1
Lesion type
Squamous cell carcinoma in situ 20
Invasive squamous cell carcinoma 1 (lesion understaged)
Lesion location
Trachea 4
Right main stem bronchus 3
Left main stem bronchus 2
Right upper lobe 1
Left upper lobe 4
Right middle lobe 4
Right lower lobe 2
Right bronchus intermedius 1
No. of lesions/patient
1 13
2 4
Previous treatment
Surgery 8
Radiation 6
Chemotherapy 6
Photodynamic therapy 2
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biopsy-conﬁrmed CIS or MIC, deﬁned as lesions radio-
graphically occult and not deﬁnable by conventional CT
scans of the chest; age 18 years; men or women using
medically acceptable methods of birth control; patients
with an Eastern Cooperative Oncology Group score of
0 to 2; patients with no contraindications for bron-
choscopy; and patients with underlying lung disease
judged by the treating clinician to be able to withstand
mucus/debris at the site of treatment.
Patient exclusion criteria included the following:
porphyria or hypersensitivity to porphyrins or
porphyrin-like agents; impaired hepatic alkaline phos-
phatase or serum glutamic oxaloacetic transaminase
levels more than three times the upper normal limits;
minimal impairment of renal function (i.e., total serum
bilirubin, >3 mg/dL; serum creatinine, >3 mg/dL); and
a white blood cell count of <4000, a platelet count of
<100,000, and a prothrombin time exceeding 1.5 times
the upper normal limit. After one patient with severe
COPD suffered a DLT, evidence of worsening pulmonary
symptoms or COPD exacerbation (i.e., worsening dys-
pnea from baseline, fevers, increased amount of sputum,
or increased purulence/change in color of sputum) that
would preclude multiple bronchoscopies and myocardial
infarction or unstable angina in the previous 6 months
were added as exclusion criteria.
Ten lung and three head and neck cancer patients
had previous treatments (Table 1). However, none of the
patients had received any chemotherapy or radiation
within the 6 months before enrollment in this trial. The
patients were diagnosed with airway CIS/MIC by our
AFB surveillance or were referred from outside facilities.
The Lam classiﬁcation was used to classify areas seen on
bronchoscopic evaluation into class I, II, and III under
both autoﬂuorescent and white lights.20 Brieﬂy, class I
indicates normal ﬁndings, class II suggests possible ab-
normality (i.e., inﬂammation on white light examination
or slight brownish indistinct area under autoﬂuorescent
light), and class III indicates a highly suspicious area
(e.g., thickened, nodular, or polypoid area under white
light and brown or brownish-red area under auto-
ﬂuorescent light). The patients underwent endobron-
chial biopsy procedures of abnormal areas (class II or
III) under AFB guidance at the RPCI to deﬁne the extent
of airway abnormality. Repeat biopsy specimens were
obtained from all referred patients for internal conﬁr-
mation of CIS/MIC. The detailed pretreatment evaluation
included a history and physical examination, a perfor-
mance status assessment, an evaluation of comorbidities,
and laboratory studies (i.e., baseline electrocardiogram,
complete blood cell count, prothrombin and partial
thromboplastin times, and serum chemistry). If a recent
CT scan of the chest was not available for review, onewas performed to exclude local extension, and whole
body positron emission tomogram (PET) scans were
performed as needed to exclude local extensions or
distal metastases. Radial balloon problem endobronchial
ultrasonography became available at our facility in 2012
and was used to evaluate the last two patients. In-
dividuals with multicentric lesions deﬁned as more than
one separate lesion per site or at different sites were
included in this study.Photodynamic Therapy
HPPH was administered in an outpatient setting by
intravenous infusion 44 to 50 hours before light delivery,
and vital signs were monitored for 15 minutes post-
infusion. Laser light treatment occurred in the Ambula-
tory Surgery Center under monitored deep sedation or
general anesthesia to allow precise delivery of light to the
target area. Each lesion was illuminated by a treatment
ﬁber that was positioned in the airway adjacent to the
index lesion. A tunable dye laser delivered light of 665 ±
3 nm using optical diffuser ﬁbers of 1.0 to 2.5 cm in
length. The irradiance was 300 to 400 mW/cm2, and the
light dose was escalated starting from 75 J/cm2 to 85, 95,
125, and 150 J/cm2, respectively. The treatment ﬁeld
included the visible lesion and an approximate 5-mm
margin around the lesion. Each lesion was treated to
February 2016 HPPH PDT for Lung Carcinoma In Situ 237the desired light dose level determined in the protocol.
Some patients had two qualifying lesions that were
treated with two separate light treatments at the same
light dose. After treatment, patients were monitored in
the Ambulatory Center by a physician and hospitalized
for 2 days until they underwent a repeat bronchoscopy
for endoscopic removal of post-PDT debris and mucus
plugs. All patients were instructed to avoid exposure to
sunlight or bright indoor light for at least 7 days by
wearing protective clothing and sunglasses provided by
the RPCI PDT center. They were also advised to expose
small areas of skin to sunlight on day 8 for 10 minutes to
detect any remaining photosensitivity.
Patient Follow-Up
Whenever possible, patients were evaluated approx-
imately 1 week, 1 month, and 6 months after treatment
to assess PDT-related toxicities and clinical responses.
Biopsy specimens obtained for assessment of treatment
responses were taken at 1- and 6-month visits. There-
after, patients were examined at 3- to 6-month intervals
at the discretion of the physician as long as they
participated in the lung cancer screening program.
Patient Assessments
Safety. Patients were monitored for systemic toxicity
during HPPH administration, laser treatment, and each
follow-up visit. The occurrence of adverse events (AEs)
during the ﬁrst 30 days posttreatment was recorded
using the revised National Cancer Institute’s Common
Terminology Criteria for Adverse Events.21 At each clinic
visit, patients were examined for local normal tissue
toxicity, performance status, pain level, and skin photo-
toxicity. All AEs and serious AEs (SAEs) were docu-
mented as to onset and resolution date, classiﬁcation of
intensity, relationship to treatment, action taken, and
outcome. AEs and SAEs were recorded as per Medical
Dictionary for Regulatory Activities coding.
Response. CIS/MIC lesions do not usually cause any
signiﬁcant narrowing of airway lumen, and visual
assessment of partial responses is therefore unreliable.
Responses were assessed using only pathology of the
lesions at follow-up bronchoscopy. Tumor and lesion
response to therapy was graded as follows: complete
response (CR)—absence of malignant cells on follow-up
endobronchial biopsy specimens; no response (NR)—
persistence of CIS/MIC on follow-up endobronchial bi-
opsy specimens.
Results
The details of patient and lesion characteristics are
shown in Table 1. Seventeen patients were enrolled.Thirteen patients had one lesion treated, while four pa-
tients had two distinct lesions treated with the same light
dose. All lesions except one were CIS/MIC, and none had
been treated previously. The lesionswere examined under
autoﬂuorescent light and white light during bronchos-
copy, and all lesions were found to be class II or III under
both lights. The lesions were predominantly hyperplastic
(14 of 21), few were nodular (6 of 21), and only one lesion
was polypoidal, which is similar distribution to what has
been reported previously.22,23 Although autoﬂuorescent
light examination helps in determining the extent of the
lesion, the lesions tend to be irregular—involving carinas
and circumference of the bronchial tree to various
degrees—and determining the exact dimensions by
bronchoscopy can be challenging. We used the laser ﬁber,
which was slightly longer than the dimensions of the le-
sions, to cover the entire abnormal area. Almost all lesions
were <2 cm in length, because the length of laser ﬁber
used was 1 cm in 11 lesions, 1.5 cm in three lesions, 2 cm
in six lesions, and 2.5 cm in one lesion. One lesion in the
150 J/cm2 light dose cohort appeared to have been inva-
sive carcinoma as revealed during subsequent bronchos-
copy by radial balloon probe endobronchial ultrasound
(EBUS), which revealed cartilage invasion.
Ten patients had experienced previous lung cancer
and three patients had had previous head and neck
cancer; all had received previous treatment. Eight pa-
tients had previous surgical resections: ﬁve had a lo-
bectomy, one had two lobectomies, and two had
pneumonectomy. Six patients had received chemo-
therapy and six had received radiation therapy. Three
patients (total three lesions) had CIS/MIC in the ﬁeld of
previous lung radiation, two patients (three lesions) had
previous radiation treatment to the contralateral lung,
and one patient (one lesion) had a history of radiation to
the head and neck area. Two patients had received
porﬁmer sodium PDT to different CIS lesions several
months before enrollment in this trial. Four patients had
no previous cancer or previous treatment.
All patients had a history of tobacco abuse, and most
of them had signiﬁcant comorbidities. Nine patients had
known cardiac disease, including coronary artery dis-
ease or congestive heart failure. Thirteen patients had
COPD (six documented as severe and two on oxygen),
and two additional patients had a loss of lung function
because of previous treatment (two separate lobec-
tomies in one patient and another with lobectomy and
radiation therapy). Only one patient had normal pul-
monary function tests.Adverse Events
Grade 1 and 2 bronchial secretion retention (mucus
plugs), an expected side effect in bronchial PDT and
Table 2. Lesion Responses by Treatment Light Dose
(1 Month Posttreatment)
Light Dose (J/cm2) No. of Lesions (Responses)
75 5 (3 CR, 2 NR)
85 3 (2 CR, 1 not evaluated)
95 4 (3 CR, 1 not evaluated)
125 4 (3 CR, 1 NR)
150 5 (3 CR, 1 NR,a 1 not evaluated)
aLesion was invasive carcinoma and was understaged before
treatment.
CR, complete response; NR, no response.
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tients distributed over all light dose cohorts. Grade 1 and
2 pain or cough occurred rarely. Four patients experi-
enced grade 1 erythema and one patient experienced
slight photophobia. Likely unrelated events included a
patient developing myocardial infarction 2 months after
treatment and another patient with history of stroke,
atrial ﬁbrillation, and polycythemia vera having a cere-
brovascular accident 1 month after treatment. This was
attributed to signiﬁcant underlying risk factors and the
patient’s hypercoagulable state.
The only possibly PDT-related SAE and DLT, a
myocardial infarction and pneumothorax, occurred in the
highest light dose cohort (150 J/cm2) in a patient with
severe COPD who had three areas of CIS and had an un-
eventful diagnostic AFB. The patient developed COPD
exacerbation before PDT therapy but did not share his
worsening symptoms with the investigators to avoid a
delay in PDT treatment. During PDT bronchoscopy, thick
mucopurulent secretions were seen in the airway.
Because the patient had already received systemic HPPH,
the investigators decided to treat him, but only one area
of CIS (right middle lobe opening) was treated. In spite of
this precaution, the patient developed signiﬁcant mucus
plugging of his right main stem and developed chest pain
and an elevated troponin I level (2.6 ng/mL) after several
hours. This delayed his bronchoscopy for removal of
mucus plugs, and he required emergent intubation. A
right-sided pneumothorax was attributed to intrinsic
positive end expiratory pressure and pulmonary hyper-
inﬂation during resuscitation. The patient improved after
removal of the mucus plug with bronchoscopy. Cardiac
catheterization revealed 80% stenosis of the right coro-
nary artery with probable insufﬁcient ﬂow reserve during
times of respiratory failure. He had complete recovery to
his baseline status and was discharged home. This SAE
prompted the addition of evidence of recent exacerbation
of chronic pulmonary disease (i.e., worsening dyspnea
from baseline, fevers, and increased purulence or change
in color of sputum) and evidence of unstable angina or
recent myocardial infarction (in the previous 6 months)
to the study exclusion criteria. Because of this DLT, we
added three more patients to this light dose cohort. Un-
fortunately, only two more patients (a total of ﬁve pa-
tients at this dose group) could be recruited because of an
interruption in HPPH supply. Therefore, although no
more DLTs occurred, an MTD could not be ﬁrmly estab-
lished. Accordingly, a light dose of 125 J/cm2 appears
prudent for future HPPH PDT of endobronchial CIS/MIC.Responses
Lesion responses by light dose are presented in
Table 2. A total of 21 lesions in 17 patients were treatedand 14 patients (18 lesions) had follow-up broncho-
scopic evaluation after 1 month. Three patients (with
one treated lesion each) did not undergo bronchoscopy
at 1 month. One of these patients decided not to have
follow-up bronchoscopy at 1 month because of initiation
of chemotherapy for lung cancer not related to the CIS
lesion, another suffered a stroke, and the third patient
was unable to withstand repeat bronchoscopy (this pa-
tient had a SAE at 150 J/cm2). Of the 18 lesions, 17 were
CIS and one was invasive carcinoma (determined retro-
spectively). Among the 17 CIS/MIC lesions, 13 achieved a
biopsy-proven CR at 1 month posttreatment. One patient
was judged to have invasive cancer based on the endo-
bronchial biopsy specimen obtained at the 1-month
follow-up appointment. Upon lobectomy 2 months
later, no cancer was detected. This patient was also
considered a CR, bringing the CR rate for CIS to 14 of
17 (82.4%) at 1 month (Fig. 1). CR occurred in all light
dose cohorts, and no light dose response was apparent in
these small samples.
Eleven lesions in nine patients with previous CR
could be reevaluated with AFB and endobronchial bi-
opsy procedures at 6 months. Of these, eight lesions in
six patients were still CR and three single lesions in three
separate patients had recurred, bringing the CR to 72.7%
(8 of 11) at 6 months in this evaluable group. Four pa-
tients with a total of ﬁve lesions opted for longer follow-
up and had serial autoﬂuorescent bronchoscopies for an
additional 1, 2, 2, and 5 years, respectively, and
remained in CR.
Management of Patients with No Response. Three
patients had NR (had remaining CIS on endobronchial
biopsy) at 1 month. One of these was thought have been
understaged based on radial EBUS. Of the remaining two
patients with three lesions who had NR at the 1-month
bronchoscopy procedure, one patient had PDT with
porﬁmer sodium to two separate lesions 3 months
subsequent to HPPH PDT and decided not to undergo
any further bronchoscopies and was lost to follow-up.
Another patient with CIS in the left upper lobe
Patients: 17
Lesions: 21
Patients: 13
Lesions: 17
1 Patient/1 Lesion: Resection at 2 months, 
counted as CR at one month
1 patient/2 lesion: didn’t have bronchoscopy
Bronchoscopy 1 month
HPPH PDT Treatment 
Patients: 2
Lesions: 3
Patients: 11
Lesions: 14
Complete Response (14/17=82.4%) No Response
Bronchoscopy 6 month
Complete Response (8/11=72.7%) Recurrence
Patients: 6
Lesions: 8
Patients: 3
Lesions: 3
Patients: 9
Lesions: 11
3 Patients/3 Lesions: No follow up bronchoscopy
1 patient/1 lesion: under- staged
Figure 1. Flowchart showing overall treatment response to
photodynamic therapy with 2-[1-hexyloxyethyl]-2 devinyl
pyropheophorbide-a.
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treated with porﬁmer sodium and had a CR.
Of the three patients who had recurred at 6 months,
one was lost to follow-up and two were treated with
porﬁmer sodium but did not undergo follow-up bron-
choscopies to determine response because of underlying
cardiopulmonary issues and patient preference.
Discussion
This study shows that HPPH is safe and has favorable
toxicity proﬁle when compared to historical controls of
porﬁmer sodium. It is also the ﬁrst to evaluate its use for
bronchogenic CIS/MIC. In this small cohort of patients,
we observed a promising CR rate of 82.4% and 72.7% of
evaluable lesions at 1 and 6 months, respectively. This is
within the range of response rates obtained by other
studies with porﬁmer sodium.4,6,8,9,24 All patients were
smokers; four of the patients had multiple lesions, and
several patients had a history of lung cancer. This is not
unusual; a recent report describes a rate of 34.4% for
multiple primary lung cancers in their cohort treated
with PDT for CIS/MIC.25
Based on this and several other studies, an HPPH dose
of 4 mg/m2 appears to be effective.13–15 A 2-day drug/
light interval was allowed in this trial. In more recently
initiated studies, the drug/light interval has been
reduced to w24 hours based on pharmacokinetic
studies26 yielding at least comparable effectiveness.14,15Although a maximally tolerated light dose could not be
ﬁrmly established, the one SAE/DLT that occurred at 150
J/cm2 suggests that the light dose should not exceed 125
J/cm2. The absence of any discernible light dose depen-
dence of treatment responses is reminiscent of studies in
early esophageal13 and oral14 cancer, and again suggests
that PS uptake and retention in the cancerous lesion may
be the dominant determinant of response. HPPH reten-
tion may be deﬁcient in some lesions, as has been shown
in recent studies of lung and oral cancers.27 Additional
clinical studies are needed to determine whether even
lower light doses might be effective. Patient selection
must be restricted to patients who can withstand
repeated bronchoscopies, allowing for removal of PDT-
induced debris and mucus plugs. These develop almost
universally after PDT, regardless of the PS used.7 Failure
of timely debris removal may lead to serious conse-
quences, as encountered in one patient with severe COPD
who suffered a myocardial infarction shortly after treat-
ment. No SAEs occurred in any of the other patients.
Slight pain or cough was observed rarely, and general
photosensitivity was negligible. This shows that patients
with CIS/MIC of airway can be treated with HPPH with
signiﬁcantly less concern of photosensitivity compared to
porﬁmer sodium, where a much higher rate of photo-
sensitivity and skin burns (13–41% when treating
CIS/MIC) has been historically reported.8 All patients
needed sunlight precautions for 7 to 10 days only
compared to 4 to 6 weeks needed for the most commonly
used (and US Food and Drug Administration–approved)
porﬁmer sodium (Photofrin). The HPPH supply is
expected to resume soon for additional clinical trials.
HPPH is currently being prepared under commercial
manufacturing practices and a new investigational new
drug application will be submitted shortly to the US Food
and Drug Administration.
Only preliminary insights into treatment response
can be gleaned from this study, which was limited by the
low patient numbers despite its long duration. Low pa-
tient accrual was caused by the low yield of detection of
CIS/MIC in the central airways, which has been similarly
reported in other studies.28 The rate of squamous cell
cancer, which tends to be central, has been declining,
especially in men.29 This makes it challenging to recruit
patients who both qualify for the study and are willing to
enroll. Long-term evaluation is also problematic in this
patient population—that is, it is difﬁcult to perform
frequent bronchoscopies on these high-risk patients,
many of whom tend to have multiple comorbidities and
may not be willing to undergo additional bronchoscopic
procedures. Although some patients did have longer
follow-up bronchoscopies and did not show any long-
term adverse sequele in the airway, it would have
been ideal to have longer follow-up bronchoscopic
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dently conﬁrm the absence of any long-term airway
complications. These are extremely infrequent with PDT,
and none have been reported in studies where long-term
follow-up was done.25,30 The small sample size pre-
cludes us from making any conclusion about the HPPH
PDT response rate based on lesions being nodular, hy-
perplastic, or polypoidal. An additional confounding
factor in studies of CIS/MIC is that it is difﬁcult to
evaluate the depth of invasion, even with high-resolution
CT and PET imaging, both of which were recommended
in previous studies. Understaging can therefore occur.
Radial balloon probe EBUS has been shown to be helpful
in determining if there is deeper invasion into the
cartilage because deeper invasion is thought to be
associated with a poor response to PDT.31,32 One of the
latest PDT trials for CIS/MIC used optical coherence to-
mography to examine the depth of invasion.23 Although
using AFB to determine the superﬁcial extent of lesions
was a strength of our study, we did not have radial
balloon probe EBUS for the ﬁrst 15 cases, which would
have otherwise enhanced the precision of lesion
assessment. PDT studies using porﬁmer sodium have
suggested that treating CIS/MIC lesions with longitudi-
nal length >1 cm had less chance of a CR because they
tend to have deeper invasion.5,6 This perception of lack
of efﬁcacy of PDT of CIS/MIC >1 cm and cartilage in-
vasion may, however, not be true for all PS agents. In the
clinical trial of treatment of CIS with the PS mono-L-
aspartyl chlorine e6 (NPe6; talaporﬁn sodium) which
has an absorption band at 664 nm, similar to HPPH, the
authors reported good efﬁcacy of NPe6 for lesions >1
cm and with cartilage invasion.23 In that trial, the large
polypoid or nodular lesions were ﬁrst debulked with
electrocautery before PDT and the tumor depth was
studied with optical coherence tomography. In spite of
these limitations, the data presented above support
consideration of a phase II clinical trial of HPPH in early
CIS/MIC of lung with the aim to recruit more patients
and attempt longer duration of follow-up bronchoscopy.
Involving multiple centers could help with increasing
patient recruitment. In addition, the evolution of modern
bronchoscopic techniques—such as optical coherence
tomography and radial probe EBUS—along with AFB
could help in determining the size and depth of the tu-
mor in a much better fashion than the technology
available when this clinical trial was initiated.
In conclusion, PDT with HPPH can be safely used for
the treatment of CIS/MIC of the airways, with potential
effectiveness comparable to porﬁmer sodium, a much
shorter duration for light precaution, and a much lower
incidence of skin photosensitivity compared to skin
photosensitivity reported with Photofrin in previous
studies.Acknowledgments
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